Comparative outcomes of pancreatic neuroendocrine neoplasms: A population-based analysis of the SEER database



      A paucity of data exists regarding the natural history and survival outcomes of pancreatic neuroendocrine neoplasms (PanNENs), a rare histological subtype which can be classified as functional (F-PanNENs) and non-functional (NF-PanNENs). The purpose of this study is to characterize their clinicopathological features and survival outcomes in a large cohort of patients from United States.


      All patients diagnosed with F-PanNENs or NF-PanNENs between 1998 and 2018 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Patient demographic, clinicopathological features and survival outcomes were analyzed. Logistic regression analysis was used to identify factors associated with NF-PanNENs diagnosis over F-PanNENs. Cox regression analysis was utilized to determine the prognostic variables for overall survival (OS) in all PanNENs patients.


      A total of 2347 patients were identified: 1181 in the F-PanNENs group and 1206 in the NF-PanNENs group. NF-PanNENs were larger in size, poorly differentiated, more commonly found in a head pancreas location, and had increased lymph node positivity and liver involvement compared to F-PanNENs. Patients with F-PanNENs were associated better survival outcomes than those with NF-PanNENs. Diagnosis at early year, poorer differentiation, and larger tumor size were independently correlated with NF-PanNENs diagnosis. In addition, multivariable analysis determined that age, gender, year of diagnosis, marital status, tumor grade, size, stage, number, and surgical treatment were independent prognostic factors for OS of all PanNENs patients.


      The clinicopathological characteristics and survival outcomes were significantly different between NF-PanNENs and F-PanNENs. Furthermore, we identified the clinical features correlated with NF-PanNENs diagnosis over F-PanNENs.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Perri G.
        • Prakash L.R.
        • Katz M.H.G.
        Pancreatic neuroendocrine tumors.
        Curr Opin Gastroenterol. 2019; 35: 468-477
        • Ma Z.Y.
        • Gong Y.F.
        • Zhuang H.K.
        • et al.
        Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management.
        World J Gastroenterol. 2020; 26: 2305-2322
        • Garcia-Carbonero R.
        • Capdevila J.
        • Crespo-Herrero G.
        • et al.
        Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).
        Ann Oncol. 2010; 21: 1794-1803
        • Cives M.
        • Strosberg J.R.
        Gastroenteropancreatic neuroendocrine tumors.
        Ca - Cancer J Clin. 2018; 68: 471-487
        • Das S.
        • Dasari A.
        Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?.
        Curr Oncol Rep. 2021; 23: 43
        • Bonds M.
        • Rocha F.G.
        Neuroendocrine tumors of the pancreatobiliary and gastrointestinal tracts.
        Surg Clin. 2020; 100: 635-648
        • Andreasi V.
        • Partelli S.
        • Muffatti F.
        • et al.
        Update on gastroenteropancreatic neuroendocrine tumors.
        Dig Liver Dis. 2021; 53: 171-182
        • Dasari A.
        • Shen C.
        • Halperin D.
        • et al.
        Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States.
        JAMA Oncol. 2017; 3: 1335-1342
        • Mpilla G.B.
        • Philip P.A.
        • El-Rayes B.
        • et al.
        Pancreatic neuroendocrine tumors: therapeutic challenges and research limitations.
        World J Gastroenterol. 2020; 26: 4036-4054
        • Anderson C.W.
        • Bennett J.J.
        Clinical presentation and diagnosis of pancreatic neuroendocrine tumors.
        Surg Oncol Clin. 2016; 25: 363-374
        • Ohmoto A.
        • Rokutan H.
        • Yachida S.
        Pancreatic neuroendocrine neoplasms: basic biology, current treatment strategies and prospects for the future.
        Int J Mol Sci. 2017; 18
        • Wang S.E.
        • Su C.H.
        • Kuo Y.J.
        • et al.
        Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region.
        Pancreas. 2011; 40: 253-259
        • Ye L.
        • Ye H.
        • Zhou Q.
        • et al.
        A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: new proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases.
        Int J Surg. 2016; 29: 108-117
        • Kasumova G.G.
        • Tabatabaie O.
        • Eskander M.F.
        • et al.
        National rise of primary pancreatic carcinoid tumors: comparison to functional and nonfunctional pancreatic neuroendocrine tumors.
        J Am Coll Surg. 2017; 224: 1057-1064
        • Falconi M.
        • Eriksson B.
        • Kaltsas G.
        • et al.
        ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.
        Neuroendocrinology. 2016; 103: 153-171
        • Shah M.H.
        • Goldner W.S.
        • Benson A.B.
        • et al.
        Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in Oncology.
        J Natl Compr Cancer Netw. 2021; 19: 839-868
        • Sadot E.
        • Reidy-Lagunes D.L.
        • Tang L.H.
        • et al.
        Observation versus resection for small asymptomatic pancreatic neuroendocrine tumors: a matched case-control study.
        Ann Surg Oncol. 2016; 23: 1361-1370
        • Regenet N.
        • Carrere N.
        • Boulanger G.
        • et al.
        Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: a French multicenter study.
        Surgery. 2016; 159: 901-907
        • Gratian L.
        • Pura J.
        • Dinan M.
        • et al.
        Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States.
        Ann Surg Oncol. 2014; 21: 3515-3521
        • Chivukula S.V.
        • Tierney J.F.
        • Hertl M.
        • et al.
        Operative resection in early stage pancreatic neuroendocrine tumors in the United States: are we over- or undertreating patients?.
        Surgery. 2020; 167: 180-186
        • Tsai H.J.
        • Wu C.C.
        • Tsai C.R.
        • et al.
        Second cancers in patients with neuroendocrine tumors.
        PLoS One. 2013; 8e86414
        • Hallet J.
        • Law C.H.
        • Karanicolas P.J.
        • et al.
        Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: a population-based analysis of 6271 cases.
        Cancer. 2015; 121: 2214-2221
        • Li G.
        • Tian M.L.
        • Bing Y.T.
        • et al.
        Clinicopathological features and prognosis factors for survival in elderly patients with pancreatic neuroendocrine tumor: a STROBE-compliant article.
        Medicine (Baltim). 2019; 98e14576
        • Nicholas D.R.
        Men, masculinity, and cancer: risk-factor behaviors, early detection, and psychosocial adaptation.
        J Am Coll Health. 2000; 49: 27-33
        • Leoncini E.
        • Boffetta P.
        • Shafir M.
        • et al.
        Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms.
        Endocrine. 2017; 58: 368-379
        • Brooks J.
        • Fleischmann-Mundt B.
        • Woller N.
        • et al.
        Perioperative, spatiotemporally coordinated activation of T and NK cells prevents recurrence of pancreatic cancer.
        Cancer Res. 2018; 78: 475-488
        • Muscogiuri G.
        • Barrea L.
        • Feola T.
        • et al.
        Pancreatic neuroendocrine neoplasms: does sex matter?.
        Trends Endocrinol Metabol. 2020; 31: 631-641
        • Andreasi V.
        • Muffatti F.
        • Guarneri G.
        • et al.
        Surgical principles in the management of pancreatic neuroendocrine neoplasms.
        Curr Treat Options Oncol. 2020; 21: 48
        • Centonze D.C.
        • Cinardi N.
        • Giannone G.
        Surgical resection for neuroendocrine tumors of the pancreas: a fourteen years single institutional observation.
        Eur Rev Med Pharmacol Sci. 2014; 18: 32-35
        • Tierney J.F.
        • Chivukula S.V.
        • Wang X.
        • et al.
        Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
        Surgery. 2019; 165: 644-651
        • Hill J.S.
        • McPhee J.T.
        • McDade T.P.
        • et al.
        Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.
        Cancer. 2009; 115: 741-751
        • Birnbaum D.J.
        • Turrini O.
        • Vigano L.
        • et al.
        Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
        Ann Surg Oncol. 2015; 22: 1000-1007
        • Keutgen X.M.
        • Nilubol N.
        • Glanville J.
        • et al.
        Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors.
        Surgery. 2016; 159: 311-318
        • Citterio D.
        • Pusceddu S.
        • Facciorusso A.
        • et al.
        Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver.
        Eur J Surg Oncol. 2017; 43: 380-387
        • Fujimori N.
        • Miki M.
        • Lee L.
        • et al.
        Natural history and clinical outcomes of pancreatic neuroendocrine neoplasms based on the WHO 2017 classification; a single-center experience of 30 years.
        Pancreatology. 2020; 20: 709-715
        • Khanna L.
        • Prasad S.R.
        • Sunnapwar A.
        • et al.
        Pancreatic neuroendocrine neoplasms: 2020 update on pathologic and imaging findings and classification.
        Radiographics. 2020; 40: 1240-1262
        • Guilmette J.M.
        • Nosé V.
        Neoplasms of the neuroendocrine pancreas: an update in the classification, definition, and molecular genetic advances.
        Adv Anat Pathol. 2019; 26: 13-30